Skip to main content
. Author manuscript; available in PMC: 2016 Nov 9.
Published in final edited form as: Cancer Cell. 2015 Nov 9;28(5):623–637. doi: 10.1016/j.ccell.2015.09.009

Figure 5. Decreased hnRNPA0 activity promotes cisplatin efficacy against p53-defective non-small cell lung cancer (NSCLC) in vivo.

Figure 5

(A) Schematic representation of the transplantable NSCLC model. (B) Representative bio-luminescence images before and after cisplatin treatment on Day 0 and 7. Red arrows indicate timing of cisplatin dosing. (C) Quantification of lung bio-luminecence pre-treatment and 5 days post-cisplatin treatment. Error bars represent mean +/− SEM, 3-4 animals per condition * p < 0.05. (D) Post-treatment Kaplan-Meier survival analysis of control tumor-bearing mice with or without cisplatin treatment, as indicated. (Vector n=7, vector + Cis n=7). (E) Post-treatment Kaplan-Meier survival analysis of shA0 tumor-bearing mice with or without cisplatin treatment, as indicated. (shA0(3) n=7, shA0(3) + Cis n=9). p values in D and E were calculated using the log-rank test.

See also Figure S5.